TWIST1 and non-small cell lung carcinoma: Hu et al. compared NSCLC cells sensitive and resistant to the EGFR inhibitor erlotinib and found that resistant cells exhibited increased Akt activity and an EMT phenotype, including a switch from TWIST2 to TWIST1 expression [115].